1	Proliferative	Proliferative	B-NP	JJ	O	3	NMOD	0
2	diabetic	diabetic	I-NP	JJ	O	3	NMOD	0
3	retinopathy	retinopathy	I-NP	NN	O	4	SUB	0
4	is	be	B-VP	VBZ	O	0	ROOT	0
5	associated	associate	I-VP	VBN	O	4	VC	0
6	with	with	B-PP	IN	O	5	VMOD	0
7	a	a	B-NP	DT	O	9	NMOD	0
8	low	low	I-NP	JJ	O	9	NMOD	0
9	level	level	I-NP	NN	O	6	PMOD	0
10	of	of	B-PP	IN	O	9	NMOD	0
11	the	the	B-NP	DT	O	18	NMOD	0
12	natural	natural	I-NP	JJ	B-protein	18	NMOD	0
13	ocular	ocular	I-NP	JJ	I-protein	18	NMOD	0
14	anti-angiogenic	anti-angiogenic	I-NP	JJ	I-protein	18	NMOD	3	angiogenic
15	agent	agent	I-NP	NN	I-protein	18	NMOD	0
16	pigment	pigment	I-NP	NN	I-protein	18	NMOD	0
17	epithelium-derived	epithelium-derived	I-NP	JJ	I-protein	18	NMOD	0
18	factor	factor	I-NP	NN	I-protein	10	PMOD	0
19	(	(	O	(	O	21	DEP	0
20	PEDF	PEDF	B-NP	NN	B-protein	21	DEP	0
21	)	)	O	)	O	18	NMOD	0
22	in	in	B-PP	IN	O	9	NMOD	0
23	aqueous	aqueous	B-NP	JJ	O	24	NMOD	0
24	humor	humor	I-NP	NN	O	22	PMOD	0
25	.	.	O	.	O	4	P	0

1	a	a	B-NP	DT	O	3	NMOD	0
2	pilot	pilot	I-NP	NN	O	3	NMOD	0
3	study	study	I-NP	NN	O	0	ROOT	0
4	.	.	O	.	O	3	P	0

1	Retinopathy	Retinopathy	B-NP	NN	O	2	SUB	0
2	is	be	B-VP	VBZ	O	0	ROOT	0
3	the	the	B-NP	DT	O	8	NMOD	0
4	most	most	I-NP	RBS	O	5	AMOD	0
5	common	common	I-NP	JJ	O	8	NMOD	0
6	microvascular	microvascular	I-NP	JJ	O	8	NMOD	0
7	diabetes	diabetes	I-NP	NN	O	8	NMOD	0
8	complication	complication	I-NP	NN	O	2	PRD	0
9	and	and	O	CC	O	2	VMOD	0
10	represents	represent	B-VP	VBZ	O	2	VMOD	0
11	a	a	B-NP	DT	O	13	NMOD	0
12	major	major	I-NP	JJ	O	13	NMOD	0
13	threat	threat	I-NP	NN	O	10	OBJ	0
14	to	to	B-PP	TO	O	13	NMOD	0
15	the	the	B-NP	DT	O	16	NMOD	0
16	eyesight	eyesight	I-NP	NN	O	14	PMOD	0
17	.	.	O	.	O	2	P	0

1	The	The	B-NP	DT	O	2	NMOD	0
2	aim	aim	I-NP	NN	O	6	SUB	0
3	of	of	B-PP	IN	O	2	NMOD	0
4	this	this	B-NP	DT	O	5	NMOD	0
5	study	study	I-NP	NN	O	3	PMOD	0
6	was	be	B-VP	VBD	O	0	ROOT	0
7	to	to	B-VP	TO	O	8	VMOD	0
8	address	address	I-VP	VB	O	6	PRD	0
9	the	the	B-NP	DT	O	10	NMOD	0
10	role	role	I-NP	NN	O	8	OBJ	0
11	of	of	B-PP	IN	O	10	NMOD	0
12	pro-	pro-	B-NP	JJ	O	15	NMOD	0
13	and	and	I-NP	CC	O	15	NMOD	0
14	anti-angiogenic	anti-angiogenic	I-NP	JJ	B-protein	15	NMOD	3	angiogenic
15	molecules	molecule	I-NP	NNS	I-protein	11	PMOD	0
16	in	in	B-PP	IN	O	10	NMOD	0
17	diabetic	diabetic	B-NP	JJ	O	18	NMOD	0
18	retinopathy	retinopathy	I-NP	NN	O	16	PMOD	0
19	in	in	B-PP	IN	O	10	NMOD	0
20	the	the	B-NP	DT	O	22	NMOD	0
21	aqueous	aqueous	I-NP	JJ	O	22	NMOD	0
22	humor	humor	I-NP	NN	O	19	PMOD	0
23	of	of	B-PP	IN	O	22	NMOD	0
24	the	the	B-NP	DT	O	25	NMOD	0
25	eye	eye	I-NP	NN	O	23	PMOD	0
26	.	.	O	.	O	6	P	0

1	Aqueous	Aqueous	B-NP	JJ	O	2	NMOD	0
2	humor	humor	I-NP	NN	O	3	SUB	0
3	was	be	B-VP	VBD	O	0	ROOT	0
4	collected	collect	I-VP	VBN	O	3	VC	19	collected
5	at	at	B-PP	IN	O	4	VMOD	0
6	cataract	cataract	B-NP	NN	O	7	NMOD	0
7	surgery	surgery	I-NP	NN	O	5	PMOD	0
8	from	from	B-PP	IN	O	7	NMOD	0
9	19	19	B-NP	CD	O	11	NMOD	0
10	diabetic	diabetic	I-NP	JJ	O	11	NMOD	0
11	patients	patient	I-NP	NNS	O	8	PMOD	0
12	and	and	B-PP	CC	O	8	PMOD	0
13	from	from	B-PP	IN	O	8	PMOD	0
14	13	13	B-NP	CD	O	15	NMOD	0
15	age-	age-	I-NP	NN	O	19	NMOD	0
16	and	and	O	CC	O	19	NMOD	0
17	sex-matched	sex-matched	B-NP	JJ	O	19	NMOD	0
18	normoglycemic	normoglycemic	I-NP	JJ	O	19	NMOD	0
19	controls	control	I-NP	NNS	O	13	PMOD	0
20	.	.	O	.	O	3	P	0

1	Levels	Level	B-NP	NNS	O	20	SUB	0
2	of	of	B-PP	IN	O	1	NMOD	0
3	pro-angiogenic	pro-angiogenic	B-NP	JJ	B-protein	7	NMOD	3	angiogenic
4	vascular	vascular	I-NP	JJ	I-protein	7	NMOD	0
5	endothelial	endothelial	I-NP	JJ	I-protein	7	NMOD	0
6	growth	growth	I-NP	NN	I-protein	7	NMOD	0
7	factor	factor	I-NP	NN	I-protein	16	NMOD	0
8	(	(	O	(	O	10	DEP	0
9	VEGF	VEGF	B-NP	NN	B-protein	10	DEP	0
10	)	)	O	)	O	7	NMOD	0
11	and	and	O	CC	O	16	NMOD	0
12	angiogenic	angiogenic	B-NP	JJ	O	16	NMOD	3	angiogenic
13	inhibitor	inhibitor	I-NP	NN	O	16	NMOD	0
14	pigment	pigment	I-NP	NN	O	16	NMOD	0
15	epithelium-derived	epithelium-derived	I-NP	JJ	O	16	NMOD	0
16	factor	factor	I-NP	NN	O	2	PMOD	0
17	(	(	O	(	O	19	DEP	0
18	PEDF	PEDF	B-NP	NN	B-protein	19	DEP	0
19	)	)	O	)	O	16	NMOD	0
20	were	be	B-VP	VBD	O	0	ROOT	0
21	determined	determine	I-VP	VBN	O	20	VC	0
22	.	.	O	.	O	20	P	0

1	Angiogenic	Angiogenic	B-NP	JJ	O	2	NMOD	3	Angiogenic
2	activity	activity	I-NP	NN	O	7	SUB	0
3	of	of	B-PP	IN	O	2	NMOD	0
4	the	the	B-NP	DT	O	6	NMOD	0
5	aqueous	aqueous	I-NP	JJ	O	6	NMOD	0
6	humor	humor	I-NP	NN	O	3	PMOD	0
7	was	be	B-VP	VBD	O	0	ROOT	0
8	quantified	quantify	I-VP	VBN	O	7	VC	0
9	by	by	B-PP	IN	O	8	VMOD	0
10	measuring	measure	B-VP	VBG	O	9	PMOD	0
11	its	its	B-NP	PRP$	O	12	NMOD	0
12	effect	effect	I-NP	NN	O	10	OBJ	16	effect
13	on	on	B-PP	IN	O	12	NMOD	0
14	the	the	B-NP	DT	O	15	NMOD	0
15	migration	migration	I-NP	NN	O	13	PMOD	14	migration
16	of	of	B-PP	IN	O	15	NMOD	0
17	capillary	capillary	B-NP	JJ	B-cell_type	19	NMOD	0
18	endothelial	endothelial	I-NP	JJ	I-cell_type	19	NMOD	0
19	cells	cell	I-NP	NNS	I-cell_type	16	PMOD	0
20	.	.	O	.	O	7	P	0

1	In	In	B-PP	IN	O	8	VMOD	0
2	the	the	B-NP	DT	O	4	NMOD	0
3	aqueous	aqueous	I-NP	JJ	O	4	NMOD	0
4	fluid	fluid	I-NP	NN	O	1	PMOD	0
5	,	,	O	,	O	8	P	0
6	VEGF	VEGF	B-NP	NN	B-protein	7	NMOD	0
7	levels	level	I-NP	NNS	O	8	SUB	0
8	were	be	B-VP	VBD	O	0	ROOT	0
9	increased	increase	I-VP	VBN	O	8	VC	17	increased
10	in	in	B-PP	IN	O	9	VMOD	0
11	diabetics	diabetic	B-NP	NNS	O	10	PMOD	0
12	(	(	O	(	O	24	DEP	0
13	mean	mean	B-NP	NN	O	14	NMOD	0
14	values	value	I-NP	NNS	O	21	NMOD	0
15	:	:	O	:	O	21	P	0
16	501	501	B-NP	CD	O	21	NMOD	0
17	vs.	vs.	B-PP	IN	O	16	NMOD	0
18	367	367	B-NP	CD	O	19	NMOD	0
19	pg/ml	pg/ml	I-NP	NN	O	17	PMOD	0
20	;	;	O	:	O	21	P	0
21	p	p	B-NP	NN	O	24	DEP	0
22	=	=	B-VP	SYM	O	21	NMOD	0
23	0.05	0.05	B-NP	CD	O	22	AMOD	0
24	)	)	O	)	O	9	VMOD	0
25	,	,	O	,	O	9	P	0
26	compared	compare	B-PP	VBN	O	9	VMOD	0
27	to	to	B-PP	TO	O	26	PMOD	0
28	controls	control	B-NP	NNS	O	27	PMOD	0
29	.	.	O	.	O	8	P	0

1	PEDF	PEDF	B-NP	NN	B-protein	2	SUB	0
2	was	be	B-VP	VBD	O	0	ROOT	0
3	found	find	I-VP	VBN	O	2	VC	0
4	to	to	I-VP	TO	O	5	VMOD	0
5	be	be	I-VP	VB	O	3	VMOD	0
6	decreased	decrease	I-VP	VBN	O	5	VC	18	decreased
7	in	in	B-PP	IN	O	6	VMOD	0
8	diabetics	diabetic	B-NP	NNS	O	7	PMOD	0
9	(	(	O	(	O	21	DEP	0
10	mean	mean	B-NP	NN	O	11	NMOD	0
11	values	value	I-NP	NNS	O	18	NMOD	0
12	:	:	O	:	O	18	P	0
13	2080	2080	B-NP	CD	O	18	NMOD	0
14	vs.	vs.	B-PP	IN	O	13	NMOD	0
15	5780	5780	B-NP	CD	O	16	NMOD	0
16	ng/ml	ng/ml	I-NP	NN	O	14	PMOD	0
17	;	;	O	:	O	18	P	0
18	p	p	B-NP	NN	O	21	DEP	0
19	=	=	B-VP	SYM	O	18	NMOD	0
20	0.04	0.04	B-NP	CD	O	19	AMOD	0
21	)	)	O	)	O	6	VMOD	0
22	compared	compare	B-VP	VBN	O	6	VMOD	0
23	to	to	B-PP	TO	O	22	PMOD	0
24	controls	control	B-NP	NNS	O	23	PMOD	0
25	.	.	O	.	O	2	P	0

1	In	In	B-PP	IN	O	13	VMOD	0
2	seven	seven	B-NP	CD	O	4	NMOD	0
3	diabetic	diabetic	I-NP	JJ	O	4	NMOD	0
4	patients	patient	I-NP	NNS	O	1	PMOD	0
5	with	with	B-PP	IN	O	4	NMOD	0
6	proliferative	proliferative	B-NP	JJ	O	7	NMOD	0
7	retinopathy	retinopathy	I-NP	NN	O	5	PMOD	0
8	,	,	O	,	O	13	P	0
9	the	the	B-NP	DT	O	12	NMOD	0
10	most	most	I-NP	RBS	O	11	AMOD	0
11	profound	profound	I-NP	JJ	O	12	NMOD	0
12	finding	finding	I-NP	NN	O	13	SUB	0
13	was	be	B-VP	VBD	O	29	VMOD	0
14	a	a	B-NP	DT	O	16	NMOD	0
15	significant	significant	I-NP	JJ	O	16	NMOD	0
16	decrease	decrease	I-NP	NN	O	13	PRD	18	decrease
17	of	of	B-PP	IN	O	16	NMOD	0
18	the	the	B-NP	DT	O	20	NMOD	0
19	PEDF	PEDF	I-NP	NN	B-protein	20	NMOD	0
20	level	level	I-NP	NN	O	17	PMOD	0
21	(	(	O	(	O	27	DEP	0
22	mean	mean	B-NP	JJ	O	23	NMOD	0
23	value	value	I-NP	NN	O	26	NMOD	0
24	:	:	O	:	O	26	P	0
25	237	237	B-NP	CD	O	26	NMOD	0
26	ng/ml	ng/ml	I-NP	NN	O	27	DEP	0
27	)	)	O	)	O	16	NMOD	0
28	,	,	O	,	O	29	P	0
29	whereas	whereas	O	IN	O	0	ROOT	0
30	VEGF	VEGF	B-NP	NN	B-protein	31	NMOD	0
31	levels	level	I-NP	NNS	O	32	SUB	0
32	were	be	B-VP	VBD	O	29	VMOD	0
33	comparable	comparable	B-ADJP	JJ	O	32	PRD	0
34	to	to	B-PP	TO	O	33	AMOD	0
35	diabetic	diabetic	B-NP	JJ	O	36	NMOD	0
36	patients	patient	I-NP	NNS	O	34	PMOD	0
37	without	without	B-PP	IN	O	36	NMOD	0
38	proliferation	proliferation	B-NP	NN	O	37	PMOD	0
39	(	(	O	(	O	48	DEP	0
40	mean	mean	B-NP	JJ	O	41	NMOD	0
41	value	value	I-NP	NN	O	45	NMOD	0
42	:	:	O	:	O	45	P	0
43	3153	3153	B-NP	CD	O	45	NMOD	0
44	;	;	O	:	O	45	P	0
45	p	p	B-NP	NN	O	47	SUB	0
46	=	=	B-VP	SYM	O	47	VMOD	0
47	0.003	0.003	B-NP	CD	O	48	DEP	0
48	)	)	O	)	O	36	NMOD	0
49	.	.	O	.	O	29	P	0

1	Angiogenic	Angiogenic	B-NP	JJ	O	2	NMOD	3	Angiogenic
2	activity	activity	I-NP	NN	O	11	SUB	0
3	in	in	B-PP	IN	O	2	NMOD	0
4	samples	sample	B-NP	NNS	O	3	PMOD	0
5	of	of	B-PP	IN	O	4	NMOD	0
6	patients	patient	B-NP	NNS	O	5	PMOD	0
7	from	from	B-PP	IN	O	6	NMOD	0
8	the	the	B-NP	DT	O	10	NMOD	0
9	control	control	I-NP	NN	O	10	NMOD	0
10	group	group	I-NP	NN	O	7	PMOD	0
11	was	be	B-VP	VBD	O	20	VMOD	0
12	generally	generally	B-ADJP	RB	O	13	AMOD	0
13	inhibitory	inhibitory	I-ADJP	JJ	O	11	PRD	18	inhibitory
14	due	due	B-PP	IN	O	11	VMOD	0
15	to	to	B-PP	TO	O	14	PMOD	0
16	PEDF	PEDF	B-NP	NN	B-protein	15	PMOD	0
17	,	,	O	,	O	20	P	0
18	and	and	O	CC	O	20	VMOD	0
19	inhibition	inhibition	B-NP	NN	O	20	SUB	18	inhibition
20	was	be	B-VP	VBD	O	0	ROOT	0
21	blocked	block	I-VP	VBN	O	20	VC	18	blocked
22	by	by	B-PP	IN	O	21	VMOD	0
23	neutralizing	neutralize	B-VP	VBG	B-protein	24	NMOD	0
24	antibodies	antibody	B-NP	NNS	I-protein	22	PMOD	0
25	to	to	B-PP	TO	O	24	NMOD	0
26	PEDF	PEDF	B-NP	NN	B-protein	25	PMOD	0
27	.	.	O	.	O	20	P	0

1	Likewise	Likewise	B-ADVP	RB	O	10	VMOD	0
2	,	,	O	,	O	10	P	0
3	in	in	B-PP	IN	O	10	VMOD	0
4	diabetics	diabetic	B-NP	NNS	O	3	PMOD	0
5	without	without	B-PP	IN	O	4	NMOD	0
6	proliferation	proliferation	B-NP	NN	O	5	PMOD	0
7	,	,	O	,	O	10	P	0
8	angiogenic	angiogenic	B-NP	JJ	O	9	NMOD	3	angiogenic
9	activity	activity	I-NP	NN	O	10	SUB	0
10	was	be	B-VP	VBD	O	0	ROOT	0
11	also	also	I-VP	RB	O	10	VMOD	0
12	blocked	block	I-VP	VBN	O	10	VC	18	blocked
13	by	by	B-PP	IN	O	12	VMOD	0
14	antibodies	antibody	B-NP	NNS	B-protein	13	PMOD	0
15	to	to	B-PP	TO	O	14	NMOD	0
16	PEDF	PEDF	B-NP	NN	B-protein	15	PMOD	0
17	.	.	O	.	O	10	P	0

1	We	We	B-NP	PRP	O	2	SUB	0
2	will	will	B-VP	MD	O	0	ROOT	0
3	demonstrate	demonstrate	I-VP	VB	O	2	VC	0
4	here	here	B-ADVP	RB	O	3	VMOD	0
5	that	that	B-SBAR	IN	O	3	VMOD	0
6	the	the	B-NP	DT	O	7	NMOD	0
7	level	level	I-NP	NN	O	15	SUB	0
8	of	of	B-PP	IN	O	7	NMOD	0
9	the	the	B-NP	DT	O	14	NMOD	0
10	natural	natural	I-NP	JJ	B-protein	14	NMOD	0
11	ocular	ocular	I-NP	JJ	I-protein	14	NMOD	0
12	anti-angiogenic	anti-angiogenic	I-NP	JJ	I-protein	14	NMOD	3	angiogenic
13	agent	agent	I-NP	NN	I-protein	14	NMOD	0
14	PEDF	PEDF	I-NP	NN	I-protein	8	PMOD	0
15	is	be	B-VP	VBZ	O	5	SBAR	0
16	inversely	inversely	I-VP	RB	O	15	VMOD	0
17	associated	associate	I-VP	VBN	O	15	VC	0
18	with	with	B-PP	IN	O	17	VMOD	0
19	proliferative	proliferative	B-NP	JJ	O	20	NMOD	0
20	retinopathy	retinopathy	I-NP	NN	O	18	PMOD	0
21	.	.	O	.	O	2	P	0

1	PEDF	PEDF	B-NP	NN	B-protein	2	SUB	0
2	is	be	B-VP	VBZ	O	0	ROOT	0
3	an	an	B-NP	DT	O	6	NMOD	0
4	important	important	I-NP	JJ	O	5	AMOD	0
5	negative	negative	I-NP	JJ	O	6	NMOD	0
6	regulator	regulator	I-NP	NN	O	2	PRD	0
7	of	of	B-PP	IN	O	6	NMOD	0
8	angiogenic	angiogenic	B-NP	JJ	O	9	NMOD	3	angiogenic
9	activity	activity	I-NP	NN	O	7	PMOD	0
10	of	of	B-PP	IN	O	9	NMOD	0
11	aqueous	aqueous	B-NP	JJ	O	12	NMOD	0
12	humor	humor	I-NP	NN	O	10	PMOD	0
13	.	.	O	.	O	2	P	0

1	Our	Our	B-NP	PRP$	O	2	NMOD	0
2	data	datum	I-NP	NNS	O	3	SUB	0
3	may	may	B-VP	MD	O	0	ROOT	0
4	have	have	I-VP	VB	O	3	VC	0
5	implications	implication	B-NP	NNS	O	4	OBJ	0
6	for	for	B-PP	IN	O	5	NMOD	0
7	the	the	B-NP	DT	O	8	NMOD	0
8	development	development	I-NP	NN	O	6	PMOD	0
9	of	of	B-PP	IN	O	8	NMOD	0
10	novel	novel	B-NP	JJ	O	11	NMOD	0
11	regimens	regimen	I-NP	NNS	O	9	PMOD	0
12	for	for	B-PP	IN	O	8	NMOD	0
13	diabetic	diabetic	B-NP	JJ	O	14	NMOD	0
14	retinopathy	retinopathy	I-NP	NN	O	12	PMOD	0
15	.	.	O	.	O	3	P	0

